List of Synribo drug patents

Synribo is owned by Teva Pharms Intl.

Synribo contains Omacetaxine Mepesuccinate.

Synribo has a total of 1 drug patent out of which 0 drug patents have expired.

Synribo was authorised for market use on 26 October, 2012.

Synribo is available in powder;subcutaneous dosage forms.

Synribo can be used as treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).

The generics of Synribo are possible to be released after 26 October, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6987103 TEVA PHARMS INTL Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Oct, 2026

(3 years from now)

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

Market Authorisation Date: 26 October, 2012

Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of SYNRIBO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in